Express Healthcare
Home  »  Lab Diagnostics  »  COVID-19 contributes 17 per cent to Dr Lal PathLabs Q2 FY21 revenues

COVID-19 contributes 17 per cent to Dr Lal PathLabs Q2 FY21 revenues

0 214
Read Article

Clocks 18.2 per cent hike in Q2 FY 2020-21 operating revenues over same quarter last year

Announcing their results for the quarter ended September 30, 2020, Dr. Lal PathLabs’s operating revenue increased by 18.2 per cent in Q2 FY21 to Rs. 431.9 crore versus Rs 365.6 crore in Q2 FY20.

COVID-19 contributed 17 per cent to revenue in Q2 FY21 with 3.08 lacs RTPCR tests.

Normalised EBITDA (after adjustment for stock based compensation & CSR cost) for Q2 FY21 also saw an uptick, to Rs. 134.7.0 crore versus Rs 113.5 crore in the same quarter last year.

There were corresponding increases in PBT (at Rs 116.6 crore in Q2 FY21 versus Rs 102.3 crore. in Q2 last year) and Profit after Tax (at Rs. 87.1 crore as compared to Rs 81.0 crore in Q2 last year)

An interim dividend of Rs. 6 per equity share of Rs. 10 each has been approved by the Board.

Leave A Reply

Your email address will not be published.

Attend an exclusive webinar to know more about biomarkers in diagnosis & therapy management of heart failure.
Register Now
 Introducing Smart Autoinjector: Changing the paradigm of usability, cost & size
Know More?
Are you looking for ICP-MS which can increase productivity and remove time trap from your analysis?
Know More